NLM Gateway
A service of the U.S. National Institutes of Health
Your Entrance to
Resources from the
National Library of Medicine
    Home      Term Finder      Limits/Settings      Search Details      History      My Locker        About      Help      FAQ    
Skip Navigation Side Barintended for web crawlers only

Adherence, treatment satisfaction and effectiveness of Once-Daily (QD) vs Twice-Daily (BID) antiretroviral therapy (AT), in a large prospective observational cohort (CUVA Study).

Perez-Molina JA, Arribas JR, Iribarren JA, Knobel H, Ribera E, Rubio R, Viciana P; International Conference on AIDS (15th : 2004 : Bangkok, Thailand).

Int Conf AIDS. 2004 Jul 11-16; 15: abstract no. WePeB5780.

H La Paz, Madrid, Spain

Background: Adherence is essential for successful AT but its complex treatment schedule is a barrier to adherence and hence to AT efficacy. QD-AT offers potential advantages as a consequence of lower dosing frequency and pill burden. This study began when experience with QD AT was still limited Methods: Non-interventional, multicenter, longitudinal study. Initial (I), simplification (S) and rescue (R) therapies were included. Visits were at baseline, 3 and 6 months. To assess adherence a structured validated questionnaire was used and to assess satisfaction a visual analogical scale was performed by independent consultants who interviewed patients (Pts) Results: From May to Dec/2002, 978 Pts were recruited. Average pill number was 5 in QD and 6.1 in BID [table: see text] Non-detectable VL was achieved at 6 months in 83.7% (I), 87.5% (S) and 57.4% (R), with no significant differences between QD/BID. Adherence and satisfaction with AT were both significantly better in QD vs BID (50.2% vs 43.5%) (64.8% vs 50.8%) respectively. Multivariate models disclosed as explanatory variables for AT adherence (OR): treatment satisfaction (1.6), family support (1.27), sexual transmission (1.22) and CDC stage C (0.84). AT satisfaction (OR): AT adherence (1.53), S-AT (1.42), QD (1.36), I-AT (0.85), CDC stage C (0.83) and R-AT (0.82); Non-detectable viral load (OR): I-AT (2.80), adherence (1.38), Age (1.02), R-AT (0.64) and S-AT (0.56) Conclusion QD schedules appear as effective as BID antiretroviral therapy, improving adherence and treatment satisfaction. This could positively affect treatment efficacy in the long term

Publication Types:
  • Meeting Abstracts
Keywords:
  • Antiretroviral Therapy, Highly Active
  • Drug Therapy, Combination
  • Humans
  • Longitudinal Studies
  • Prospective Studies
  • Viral Load
  • drug therapy
  • epidemiology
  • therapy
Other ID:
  • GWAIDS0039491
UI: 102283707

From Meeting Abstracts




Contact Us
U.S. National Library of Medicine |  National Institutes of Health |  Health & Human Services
Privacy |  Copyright |  Accessibility |  Freedom of Information Act |  USA.gov